MD 920
Alternative Names: MD 920G; MD-921Latest Information Update: 15 Apr 2016
Price :
$50 *
At a glance
- Originator Aus Bio Limited
- Class
- Mechanism of Action Cell stimulants; Growth modulators; Nitric oxide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma; Wounds
Most Recent Events
- 19 Apr 2010 Phase-I development is ongoing in Australia
- 06 Jan 2005 Phase-I clinical trials in Wounds in Australia (unspecified route)